drugset

drugset / Trial / NCT06396429

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

NCT06396429 ↗

Phase 3 Completed 567 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.

Timeline

Start: 2024-05-13
Primary completion: 2025-07-07
Completion: 2025-07-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS9531	Unknown	—	Other

Indications